CA 2729 CA 153 Breast Cancer Markers Panel Test
Introduction
The CA 2729 CA 153 Breast Cancer Markers Panel Test is a significant diagnostic tool designed to aid in the early detection and monitoring of breast cancer. This test measures specific tumor markers that can indicate the presence of breast cancer, allowing for timely intervention and treatment. Understanding your risk factors and symptoms is crucial, and this test provides a pathway to proactive health management.
What the Test Measures
This panel test specifically detects the levels of CA 2729 and CA 153 markers in the blood. Elevated levels of these markers can be associated with breast cancer, making them essential for oncologists and gynecologists in assessing a patient’s condition.
Who Should Consider This Test
- Women with a family history of breast cancer.
- Individuals experiencing symptoms such as unusual lumps, changes in breast shape, or discharge.
- Patients undergoing treatment for breast cancer who need monitoring.
Benefits of Taking the Test
- Early detection of potential breast cancer.
- Monitoring of existing breast cancer conditions.
- Guidance for treatment decisions and management.
Understanding Your Results
Results from the CA 2729 CA 153 Breast Cancer Markers Panel Test will indicate the levels of the tumor markers. Elevated levels may require further investigation or intervention. It is essential to discuss your results with your healthcare provider to understand the implications for your health.
Test Name and Price
| Price Type | Price (NGN) |
|---|---|
| Discount Price | 260,000 NGN |
| Regular Price | 360,000 NGN |
Book the Test
To book the CA 2729 CA 153 Breast Cancer Markers Panel Test, please call or WhatsApp us at +2348077798758. Taking charge of your health has never been easier. Don’t wait—get tested today!
Additional Information
Turnaround Time: Daily (LPL), Sample by the 7th of the month; Report after 2-3 weeks.
Sample Type: 2 mL (1 mL min.) serum from 1 SST. Ship refrigerated or frozen. Provide brief clinical history.
Method: CMIA, Immunoassay.
Specialty: Oncologist, Gynecologist.
